Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I study of TMC589337 and TMC589354 alone and with TMC310911 in healthy volunteers
NL-OMON33338Phase 1Active, not recruiting
- Sponsor
- Tibotec
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TMC589337, TMC589354 and TMC-310911 in human immunodeficiency virus infection (HIV), sponsored by Tibotec. Primary endpoints: Safety and tolerability after ascending single oral doses of TMC589337 and TMC589354, Pharmacokinetics of TMC589337 and TMC589354 after ascending single oral doses and 2 more. Started May 2009; status: active, not recruiting.
02
Drugs
TMC589337TMC589354TMC-310911
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON33338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33338.